QQ客服 官方微博 反馈留言

	Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
	Shi, Y.; Dong, M.; Hong, X.; Zhang, W.; Feng, J.; Zhu, J.; Yu, L.; Ke, X.; Huang, H.; Shen, Z.
刊名	ANNALS OF ONCOLOGY
	2015
卷号	26期号:8
关键词	chidamide HDAC inhibitor epigenetic T-cell lymphoma pivotal trial
ISSN号	0923-7534
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4874536
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Shi, Y.,Dong, M.,Hong, X.,et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma[J]. ANNALS OF ONCOLOGY,2015,26(8).
APA	Shi, Y..,Dong, M..,Hong, X..,Zhang, W..,Feng, J..,...&Lu, X..(2015).Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.ANNALS OF ONCOLOGY,26(8).
MLA	Shi, Y.,et al."Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma".ANNALS OF ONCOLOGY 26.8(2015).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。